Simon is Entrepreneur-in-Residence at Atlas Ventures, Boston, US. Prior to joining Atlas, Simon was CSO at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma in 1Q 2020. Simon brings to Oxstem more than 25 years of R&D experience including leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech. Simon has worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Simon is a member of the Technology Development Fund for Boston Children’s Hospital, an innovation fund focused on diseases of children, a Fellow of the Royal Society of Medicine and is well published, having authored over 50 articles in peer reviewed journals.
Simon Read Ph.D